TITLE:
The Lebanese Society of Cardiology Consensus Statement on the Use of Natriuretic Peptides for the Management of Heart Failure
AUTHORS:
Tony Abdel Massih, Hadi Skouri, Antoine Sarkis, Malek Mohammad, Abbas Alaaeddine, Jean Paul Sahakian, James Januzzi
KEYWORDS:
Acute Heart Failure, Chronic Heart Failure, Natriuretic Peptides, NT-proBNP, BNP, Algorithm
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.13 No.6,
June
30,
2023
ABSTRACT: Plasma concentration of Natriuretic Peptide (NP) is a valuable diagnostic tool for heart failure (HF). It can help rule out or confirm a diagnosis of HF based on symptoms, but its use is not clearly defined. NPs should be used in conjunction with physical examination and other diagnostic tests. However, it is important to note that several conditions besides the diagnosis of HF may cause NPs levels to be elevated. Additionally, there are situations when NP concentrations may be below diagnostic thresholds in[1]. This consensus statement aims to provide a straightforward diagnostic flowchart for clinicians in both the emergency department and outpatient settings to aid in diagnosing both acute and chronic HF. The diagnosis of acute HF can be ruled out with a BNP level of 100 pg/mL or NTproBNP level of 300 pg/mL, regardless of the patient’s age. To identify HF, a 3-level cut-off point based on the patient’s age is recommended. Chronic heart failure can be ruled out with a BNP level of 35 pg/mL or NTproBNP level of 125 pg/mL, regardless of thepatient’s age[1].